Beyond Identity Accelerates Path to FedRAMP Certification with RapidFort, Slashing Time and Costs
Partnership fast-tracks access to government markets and simplifies compliance
SAN FRANCISCO, April 09, 2025--(BUSINESS WIRE)--RapidFort, the fastest growing cybersecurity company securing the global software supply chain, has partnered with Beyond Identity, a leading provider of identity and access management solutions, to reduce the time and costs of FedRAMP certification. By working together with RapidFort, Beyond Identity shortened the certification process by three months and cut associated costs by 50%, outperforming alternative approaches and cementing its credibility in the government sector.
"RapidFort was an excellent and comprehensive partner during our FedRAMP journey," says Borislav Ivanov, Engineering Manager, Site Reliability Engineering at Beyond Identity. "They cut the cost of image hardening and SSDLC efforts by 50%, shaved three months off our overall compliance timeline, and delivered outstanding support every step of the way."
Achieving FedRAMP certification is a crucial and complex process for any organization looking to provide solutions to the federal government, demanding extensive documentation, security testing, and ongoing compliance efforts. Beyond Identity wanted to streamline this process and reduce overall certification costs, all without overburdening its engineering team.
RapidFort played a critical role in helping Beyond Identity earn its certification, while achieving its budgetary and process goals in 3 key ways:
Simplified the compliance process with pre-hardened, near-zero CVE Curated Images aligned with NIST 800-70, FIPS 140-2, and 140-3 standards, establishing a secure foundation, and cutting through a significant portion of the initial compliance work.
Streamlined the benchmarking process with their automated scanning tools, ensuring Security Technical Implementation Guide (STIG) hardened applications.
Automatically generated the necessary compliance documentation, including Plan of Action and Milestones (POAM) and Software Bill of Materials (SBOM), further reducing labor-intensive work.
"Our customers are developing cutting-edge security solutions for both the private and public sectors, so it's imperative that their offerings are approved for government use as quickly as possible," said Mehran Farimani, CEO of RapidFort. "We're proud to be setting the industry standard for FedRAMP certification support, streamlining a traditionally formidable process, and strengthening the infrastructure that helps secure our nation."
RapidFort, already available through Platform One, Tradewind Marketplace, AWS Marketplace, Microsoft Azure Marketplace, Google Cloud Marketplace, and Carahsoft, provides a reliable and efficient pathway for organizations looking to enter the federal marketplace and drive growth in the government sector. For more information about the RapidFort platform, please visit: https://www.rapidfort.com/
About RapidFort
RapidFort offers a cybersecurity platform that streamlines and secures modern infrastructure. Their innovative approach allows organizations to continuously monitor and minimize their software attack surface, ultimately improving their security posture and operational efficiency. RapidFort empowers development and security teams with a free tier and free community images, making it easy to get started with secure software development. Learn more about RapidFort at https://www.rapidfort.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409859559/en/
Contacts
Cole ChristyLaunchTech Communications619-972-9836cole@golaunchtech.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
KBRA Assigns Preliminary Ratings to Upstart Securitization Trust 2025-2
NEW YORK, June 11, 2025--(BUSINESS WIRE)--KBRA assigns preliminary ratings to four classes of notes issued by Upstart Securitization Trust 2025-2 ("UPST 20252"), a $294.51 million consumer loan ABS collateralized by unsecured consumer loans. The preliminary ratings reflect initial credit enhancement levels of 58.75% for the Class A notes, 45.90% for the Class B notes, 36.20% for the Class C notes and 20.50% for the Class D notes. Credit enhancement consists of overcollateralization, excess spread, a non-declining cash reserve account and subordination (except for the Class D notes). UPST 2025-2 represents the 46th ABS securitization collateralized by unsecured consumer loans originated through the online platform operated by Upstart Network, Inc. ("Upstart" or the "Company"), a 100% owned subsidiary of the publicly traded entity Upstart Holdings, Inc. (NASDAQ: UPST). KBRA applied its Consumer Loan ABS Global Rating Methodology, as well as its Global Structured Finance Counterparty Methodology and ESG Global Rating Methodology as part of its analysis of the portfolio pool data, underlying collateral pool and capital structure. KBRA considered its operational reviews of Upstart, as well as periodic update calls with the Company. Operative agreements and legal opinions will be reviewed prior to closing. To access ratings and relevant documents, click here. Click here to view the report. Methodologies ■ ABS: Consumer Loan ABS Global Rating Methodology ■ Structured Finance: Global Structured Finance Counterparty Methodology ■ ESG Global Rating Methodology Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1009880 View source version on Contacts Analytical Contacts Michael Polvere, Director (Lead Analyst) +1 646-731-3339 Vicky Xiao, Senior Analyst +1 646-731-1422 Melvin Zhou, Managing Director (Rating Committee Chair)+1 646-731-2412 Business Development Contact Arielle Smelkinson, Senior Director +1 646-731-2369 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
KBRA Assigns Preliminary Ratings to Upstart Securitization Trust 2025-2
NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to four classes of notes issued by Upstart Securitization Trust 2025-2 ('UPST 20252'), a $294.51 million consumer loan ABS collateralized by unsecured consumer loans. The preliminary ratings reflect initial credit enhancement levels of 58.75% for the Class A notes, 45.90% for the Class B notes, 36.20% for the Class C notes and 20.50% for the Class D notes. Credit enhancement consists of overcollateralization, excess spread, a non-declining cash reserve account and subordination (except for the Class D notes). UPST 2025-2 represents the 46th ABS securitization collateralized by unsecured consumer loans originated through the online platform operated by Upstart Network, Inc. ('Upstart' or the 'Company'), a 100% owned subsidiary of the publicly traded entity Upstart Holdings, Inc. (NASDAQ: UPST). KBRA applied its Consumer Loan ABS Global Rating Methodology, as well as its Global Structured Finance Counterparty Methodology and ESG Global Rating Methodology as part of its analysis of the portfolio pool data, underlying collateral pool and capital structure. KBRA considered its operational reviews of Upstart, as well as periodic update calls with the Company. Operative agreements and legal opinions will be reviewed prior to closing. To access ratings and relevant documents, click here. Click here to view the report. Methodologies ■ ■ Structured Finance: Global Structured Finance Counterparty Methodology ■ ESG Global Rating Methodology Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www. About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1009880
Yahoo
2 hours ago
- Yahoo
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. 'It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon,' said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or follow us on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact:Pete Rahmerprahmer@ Media:Dan Budwick1AB973-271-6085dan@
